TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26114379
Drug: Delayed-release (DR)
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release (DR) prednisone
Study: 2840815
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg
Study: 21980964
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lisinopril 10 mg and diclofenac sodium 100 mg
Study: 17063170
Drug: P400 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: P400 (400 mg phosphate)
Study: 17063170
Drug: P800 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: P800 (800 mg phosphate)
Study: 17063170
Drug: P1200 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1200 (1200 mg phosphate)
Study: 12622767
Drug: Tegaserod (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (6 mg b.d.)
Study: 8368545
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of morphine
Study: 6362490
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of epinephrine
Study: 8368545
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.2 mg of morphine and 0.2 mg of epinephrine
Study: 3545737
Drug: Amiloride HCl
Normalized name: amiloride HCl
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride HCl 5 mg + Hydrochlorothiazide 50 mg (AHCZ)
Study: 29309832
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (300,000 IU oral doses at 8 weeks interval)
Study: 18378381
Drug: Atorvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (5 mg/day)
Study: 14522295
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination (Cosopt)
Study: 10795763
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium butyrate (4 g/day) plus oral mesalazine (2.4 g/day)
Study: 10795763
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine plus placebo
Study: 1571381
Drug: 0.25 g
Normalized name: AMICAR 0.25 GM/mL Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g of cefodizime
Study: 1571381
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of cefodizime
Study: 6488703
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of calcium (increased plasma calcium concentration by about 0.5 mmol/l)
Study: 6488703
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of calcium infusion after 46 min
Study: 6488703
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of sodium nitroprusside
Study: 6488703
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of noradrenaline
Study: 30284097
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure mask (CPAP), oxygen at 6 L/min, 5-15 cm H2O
Study: 30284097
Drug: Simple oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oxygen mask, oxygen at 6 L/min
Study: 16084879
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of tibolone
Study: 16084879
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of E2 plus 1 mg of norethisterone acetate (E2/NETA)
Study: 16084879
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate (CEE/MPA)
Study: 16084879
Drug: No menopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No menopausal therapy (control)
Study: 7473832
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (25 g daily)
Study: 2258344
Drug: Pefloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (800 mg per day)
Study: 2258344
Drug: Ampicillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (4 g per day) plus Gentamicin (240 mg per day im)
Study: 31669049
Drug: 975 mg
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg oral acetaminophen
Study: 17968020
Drug: Ixabepilone plus
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone plus capecitabine (Ixabepilone 40 mg/m² IV on day 1 of a 21-day cycle plus capecitabine 2000 mg/m² orally on days 1-14 of a 21-day cycle)
Study: 17968020
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (2500 mg/m² on the same schedule)
Study: 12121393
Drug: 50% tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% tea tree oil solution
Study: 12121393
Drug: 25% tea
Normalized name: IODINE 2.5 g in 1 L TOPICAL SOLUTION [DariSoft .25% Teat Dip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% tea tree oil solution
Study: 9893074
Drug: Voluntary unsupervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary unsupervised aerobic and step training (twice per week)
Study: 2185822
Drug: Mifepristone 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 0 mg (placebo)
Study: 20130470
Drug: Mifepristone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (all doses)
Study: 391754
Drug: Pindolol, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol, 15 mg/day
Study: 27977309
Drug: Coordinated inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordinated inhalation maneuver
Study: 27977309
Drug: Uncoordinated inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoordinated inhalation maneuver
Study: 26124485
Drug: New ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New ointment containing several antioxidants
Study: 26124485
Drug: New ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New ointment
Study: 23728549
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid for 14 days
Study: 21570071
Drug: Magnetic resonance-guided
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic resonance-guided focused ultrasound surgery (FUS) treatment of uterine fibroids
Study: 11034245
Drug: Intravenous 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil (5-FU) 450 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=74)
Study: 11034245
Drug: Oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral doxifluridine 900 mg/m2/day with leucovorin 20 mg/m2/day for 12 cycles (n=92)
Study: 8769611
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg intravenous hyperimmune globulin (IVIG)
Study: 1427133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Timolol and Acetazolamide
Study: 6427817
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg diazepam
Study: 6427817
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg diazepam
Study: 6427817
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg diazepam
Study: 1750018
Drug: Nebulised amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised amiloride (1 mg in 3 ml saline) via System 22 nebuliser
Study: 1750018
Drug: Nebulised amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised amiloride (1 mg in 3 ml saline) via Fisoneb nebuliser
Study: 6311242
Drug: Pectin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (12 g/d)
Study: 6311242
Drug: Cellulose (15
Normalized name: methylcellulose (15 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (15 g/d)
Study: 6311242
Drug: Lignin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignin (12 g/d)
Study: 29925775
Drug: Inulin supplement
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin supplement (10 g/day)
Study: 22492372
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 3 to 59 mg kg(‐1) d(‐1)
Study: 22492372
Drug: Current recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current recommended methionine intake of 28 mg kg(‐1) d(‐1)
Study: 22492372
Drug: Infant formulas
Normalized name: infant formulas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formulas providing methionine intake of 49-80 mg kg(‐1) d(‐1)
Study: 20307216
Drug: LUMIGAN (bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUMIGAN (bimatoprost ophthalmic solution, 0.03%)
Study: 20307216
Drug: TRAVATAN (travoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAVATAN (travoprost ophthalmic solution, 0.004%)
Study: 18508828
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF), 400 microg once daily
Study: 16996600
Drug: PDT followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDT followed by approximately 11 mg IVTA
Study: 10442963
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Study: 10442963
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl)
Study: 10442963
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.05 mg x kg(‐1))
Study: 10442963
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg x kg(‐1) with 1 microg x kg(‐1) fentanyl) and atracurium (0.1 mg x kg(‐1))
Study: 8685641
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g, i.v. every 8 h for 2 days)
Study: 8685641
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further antibiotics
Study: 8685641
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g i.v. at induction and 12 h postoperatively)
Study: 1880233
Drug: Estazolam 2
Normalized name: estazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam 2 mg
Study: 549782
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (TA) 250-750 mg/die
Study: 549782
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 50-150 mg/die
Study: 549782
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (TA) 250-1000 mg/die in congestive heart failure patients
Study: 17089219
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water treatment
Study: 16429619
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg SL Apomorphine (APO)
Study: 10998469
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg bezafibrate once daily
Study: 24655345
Drug: Conventional language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional language therapy (CLT)
Study: 22441361
Drug: S(+)‐ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine infusion for 60 hours
Study: 15572276
Drug: Risperidone (4.2±1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4.2±1.7 mg/day)
Study: 15572276
Drug: Haloperidol (8.0±3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (8.0±3.6 mg/day)
Study: 15572276
Drug: Risperidone and
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone and Haloperidol (4.1±1.8 mg/day and 7.4±3.7 mg/day respectively) during the subsequent 9 weeks
Study: 12540319
Drug: Nortriptyline (Pamelor)
Normalized name: nortriptyline Oral Capsule [Pamelor]
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (Pamelor) with weekly behavioral therapy
Study: 9703790
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite in combination with physical therapy for 3 weeks
Study: 9205761
Drug: Ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 800 mg
Study: 30779530
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (median of 22 hours daily for a median of 7 days)
Study: 26181910
Drug: High-intensity rehabilitation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity rehabilitation programme with cognitive behavioural therapy
Study: 23642951
Drug: True Individualised
Approvals — FDA: no, EMA: no, PMDA: no
Description: True Individualised Western Herbal Medicine (IWHM) tinctures
Study: 23642951
Drug: Placebo Individualised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Individualised Western Herbal Medicine (IWHM) tinctures
Study: 11315821
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (HOE 901) once daily (n = 259)
Study: 11315821
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin once or twice daily (n = 259)
Study: 11315821
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (HOE 901) once daily
Study: 11315821
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin once or twice daily
Study: 9220540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IA-2 beta and IA-2
Study: 9220540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IA-2 beta and GAD65
Study: 9220540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IA-2 and GAD65
Study: 3400843
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine alone
Study: 3400843
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine with adrenaline 1:1000
Study: 31383449
Drug: Anapanasati meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anapanasati meditation (daily for 6 months)
Study: 26226227
Drug: Insulin (2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (2-mg bovine insulin/kg body mass)
Study: 26226227
Drug: Oleate (OL)
Normalized name: oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleate (OL) (300 μg/kg)
Study: 26226227
Drug: Octanoate (OCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octanoate (OCT) (300 μg/kg)
Study: 26226227
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Oleate
Study: 26226227
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Octanoate
Study: 26226227
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution alone)
Study: 21807930
Drug: HMB/ARG/LYS (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/ARG/LYS (n = 40) with vitamin D status <30 ng 25OH-vitD(3)/mL
Study: 17135039
Drug: Cyclical hormone
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical hormone replacement therapy (HRT) with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for 1 year
Study: 17135039
Drug: 17beta-estradiol gel
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol gel with the same schedule of MPA administration for 1 year
Study: 9219145
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use before or during sex
Study: 6198057
Drug: Prioderm lotion
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prioderm lotion (0.5% malathion in isopropanol)
Study: 23792399
Drug: Single-visit root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-visit root canal treatment
Study: 18368947
Drug: Procaterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol (20 µg, inhaled three times a day)
Study: 18368947
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (200 µg, inhaled three times a day)
Study: 17165499
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Chinese medicine
Study: 11766711
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine
Study: 11100349
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (TPN) when total bilirubin > 5 mg% (Group A2)
Study: 11100349
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (TPN) when total bilirubin > 10 mg% (Group B2)
Study: 11100349
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (TPN) when total bilirubin > 20 mg% (Group C2)
Study: 11100349
Drug: Non-cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cyclic total parenteral nutrition (TPN)
Study: 8383933
Drug: Doxacurium (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxacurium (0.05 mg/kg)
Study: 8383933
Drug: Pancuronium (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.14 mg/kg)
Study: 8383933
Drug: Pipecuronium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium (0.10 mg/kg)
Study: 31615775
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of testosterone cream daily for 10 weeks
Study: 28984843
Drug: Weekly family
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly family psychosocial intervention
Study: 22648466
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg · kg‐1)
Study: 20921123
Drug: Acamprosate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (initial oral loading followed by 1998 mg daily)
Study: 9372653
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (975 mg)
Study: 3501540
Drug: FUra plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUra plus leucovorin (200 mg/m2 daily for 5 days)
Study: 3501540
Drug: FUra plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUra plus leucovorin (20 mg/m2 daily for 5 days)
Study: 30365408
Drug: 2.5% topical
Normalized name: BP 2.5% Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% topical ketoprofen gel
Study: 21562038
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate (IV MTX) during interim maintenance phases
Study: 21562038
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (PO MTX) during interim maintenance phases
Study: 19433681
Drug: Modified high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified high-dose induction phase (arm A): 4 weeks of 10 MU/m² IFN-alpha-2b IV for 2 weeks and 10 MU/m² IFN-alpha-2b SC for 2 weeks followed by 23 months of low-dose IFN-alpha-2b 3 MU SC three times a week
Study: 19433681
Drug: Low-dose IFN-alpha-2b
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IFN-alpha-2b only (arm B): 3 MU three times a week for 24 months
Study: 10990220
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg tablet once daily for 13 days)
Study: 3539163
Drug: Epoprostenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol infusion
Study: 16148284
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg once daily for seven days)
Study: 9631752
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) administered every 4 weeks, with NSAIDs initially maintained.
Study: 2969002
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone (100 micrograms/kg)
Study: 2969002
Drug: Daily and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily and alternate day prednisone treatments
Study: 25740262
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) single oral doses of 1/10/50/100/200 mg
Study: 25740262
Drug: Asunaprevir (ASV)
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir (ASV) single oral doses of 200/400/600/900/1200 mg